NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Other Prepaid Expenses and Other Current Assets

12 Months Ended

Sep. 30, 2022

5. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of September 30,		As of September 30,
	2022		2021
Prepaid research and development expense	$	805,542	$	583,267
Prepaid rent		—		172,518
Franchise tax receivable		127,715		—
Other prepaid expenses and other current assets		243,046		780,401
Total	$	1,176,303	$	1,536,186